Indian Pharmaceuticals Industry

Govt notifies incentive scheme for local API manufacturing to cut imports

According to a government notification, bulk drugs accounted for 63 per cent of total pharmaceutical imports in the country in 2018-19.

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

MPs ask govt to promote inexpensive drugs, tighten reins on pharma lobby

A dozen of the 30 MPs, who are members of the parliamentary standing committee on home affairs, headed by Congress's Anand Sharma, attended the meeting

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Govt working to select locations for bulk drug, medical device parks

Union Cabinet on March 12 had approved scheme for development of three bulk drug and four medical device parks

Pharma SMEs will overcome short-term disruptions: CRISIL SME Tracker

Short-term disruptions include high input costs and various operational challenges.

Covid-19 crisis: Race to develop vaccine gets a booster as field widens

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

KKR to acquire controlling stake in JB Chemicals for Rs 3,750 crore

The total deal size thus will be around $500 mn or around Rs 3,750 crore

Policy flip-flops may puncture India's image as 'pharmacy of the world'

India supplies almost 20 per cent of the medicines consumed by the world. Every third tablet in the US market is from India

Relief for pharma firms as govt starts clearing API imports from China

This comes after a week of economic disruption caused by introducing stringent scrutiny, resulting in shipments originating in China getting held up at Indian ports.

Covid-19 crisis: Health care workers may get vaccine after phase 2 trials

Indigenously developed Bharat Biotech's vaccine candidate Covaxin is entering human trials on Wednesday.

Shot of Hope: Equal access a hurdle after race to coronavirus vaccine

The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created

Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.

Galwan clash: Govt looks beyond China to source APIs amid Covid-19 crisis

Price and capacity constraints, however, would be big impediments.

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Covid-19 crisis: Gilead working on combo of remdesivir, other drugs

Patient recruitment for the tocilizumab combination therapy study will begin this month.

Covid-19 crisis: Drug sales in May down 9%, fiscal growth to be flat

Market research firm AIOCD AWACS has predicted zero growth in the domestic market this financial year.

Amidst controversy, Indian companies continue to manufacture HCQ

Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.

Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

30 groups in India working on coronavirus vaccine, 20 at 'good pace'

ICMR conducting study on presence of antibodies in people, results next week